BioMarin revenue rises 32% to $1.02B as quarterly net loss widens

what happened

BioMarin Pharmaceutical generated $1.02 billion in revenue in the third quarter of 2026, a 32% jump from $776.1 million a year earlier, according to TradingView, which summarized the company's SEC filing. Losses deepened, with the net loss reaching $122.8 million against $30.7 million, and the diluted loss per share rising to $0.63 from $0.16.

Product sales grew by $449.2 million over nine months, and $336.4 million of that increase came from the GALAFOLD and POMBILITI plus OPFOLDA franchises the company acquired. VOXZOGO sales advanced on new patient starts, mostly outside the United States, while PALYNZIQ and VIMIZIM also brought in more money; NAGLAZYME was the only major decline.

The FDA accepted filings seeking full approval for VOXZOGO in achondroplasia and hypochondroplasia, with decisions targeted for February and May 2027. BioMarin also expects higher amortization of acquired products and plans a $70 million license payment tied to BMN 450 in the fourth quarter of 2026.

why it matters

For investors, the key tension is strong top-line growth set against a larger loss, where amortization of acquired products plays a role. The VOXZOGO decisions due in 2027 will be the next concrete milestones to watch for the stock.

market impact

BMRN shares: strong revenue growth offset by a wider loss and rising amortization, so pressure is mixed

• ↔BioMarin shares mixed — revenue growth supports the stock while wider losses and amortization weigh on it

tags

instruments